Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kyverna Therapeutics, Inc. (Nasdaq: KYTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Kyverna is a clinical-stage biopharmaceutical company focused on CD19-targeting CAR T-cell therapies for autoimmune diseases, and its filings offer detailed information on clinical progress, financing arrangements, and governance matters.
Investors can review Form 8-K current reports in which Kyverna describes material events such as positive topline data from the KYSA-8 registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff person syndrome, interim Phase 2 data from the KYSA-6 registrational trial in generalized myasthenia gravis, and guidance on anticipated regulatory steps like a planned Biologics License Application for SPS. Other 8-K filings outline a loan and security agreement with Oxford Finance LLC, the terms of an underwritten public offering of common stock under an effective Form S-3 shelf registration statement, and leadership changes including the appointment of an Executive Chairperson of the Board.
Through this page, users can also locate references to Kyverna’s status as an emerging growth company, details on its Nasdaq-listed common stock under the ticker KYTX, and exhibits such as underwriting agreements, legal opinions, and investor presentations. Stock Titan’s interface surfaces these filings as they are made available on EDGAR and pairs them with AI-powered summaries that highlight key points, helping readers quickly understand the significance of each document without parsing all of the legal language.
For those researching KYTX, this filings hub is a central resource for tracking Kyverna’s reported clinical milestones, financial obligations, equity offerings, and board-level decisions as disclosed in its SEC submissions.
Kyverna Therapeutics has registered up to $100,000,000 of its common stock for sale in an at‑the‑market offering through Jefferies LLC acting as sales agent. Sales may occur from time to time under a Sales Agreement dated March 27, 2025, with Jefferies receiving a 3.0% commission on gross proceeds.
The prospectus shows 60,389,893 shares outstanding as of December 31, 2025 and gives an illustrative example of selling 12,594,458 shares at an assumed price of $7.94 per share resulting in up to 72,984,351 shares outstanding. Net proceeds are intended for general corporate purposes, including R&D, capital expenditures, working capital and general administrative expenses.
Kyverna Therapeutics, Inc. has registered a shelf offering to sell up to $300,000,000 of securities from time to time and included a sales agreement prospectus for up to $100,000,000 of common stock to be sold under an Open Market Sale Agreement with Jefferies LLC.
The base prospectus covers a range of instruments including common stock, preferred stock, debt securities, warrants, rights, units and depositary shares, with specific terms to be provided in prospectus supplements. The company’s common stock trades on Nasdaq under the symbol KYTX; the last reported sale price cited here was $7.87 per share as of March 25, 2026.
Kyverna Therapeutics, Inc. presents an annual overview as a late-stage clinical biopharmaceutical company developing CD19-directed cell therapies for autoimmune diseases. Its lead autologous CAR T candidate, mivocabtagene autoleucel (miv-cel / KYV-101), targets B cells to reset the immune system and aims for durable, treatment-free remission.
The company has completed a registrational Phase 2 SPS trial (KYSA-8) with a highly significant improvement in walking ability, plans a BLA filing in the first half of 2026, and has RMAT and orphan designations in SPS and MG. In generalized myasthenia gravis, positive Phase 2 data support an ongoing Phase 3 KYSA-6 trial against standard of care.
Additional programs explore miv-cel in multiple sclerosis, rheumatoid arthritis, lupus nephritis and systemic sclerosis through company and investigator-initiated studies. A next-wave autologous product, KYV-102, uses a rapid whole-blood manufacturing process, and KYV-201 is an allogeneic CD19 CAR T developed with Intellia. Kyverna states that its cash, cash equivalents and marketable securities are expected to provide runway into 2028, funding the planned SPS BLA submission, SPS commercial launch preparation and the Phase 3 gMG trial.
Kyverna Therapeutics reported its fourth quarter and full year 2025 results while highlighting major progress for its lead autoimmune CAR T therapy, miv-cel. The company is preparing a Biologics License Application for stiff person syndrome in the first half of 2026 and aims to be launch-ready by year-end 2026.
Kyverna is also advancing an FDA-aligned Phase 3 trial in generalized myasthenia gravis and reported encouraging data from investigator-initiated studies in progressive multiple sclerosis and rheumatoid arthritis. The company strengthened its balance sheet through $147.5 million in financings and ended 2025 with $279 million in cash, expecting runway into 2028 despite a 2025 net loss of $161.3 million.
Kyverna Therapeutics, Inc. reported that its Chief Financial Officer, Marc Grasso, received new equity awards as part of his compensation. He was granted a stock option for 65,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. He also received 10,000 shares of common stock in the form of a restricted stock unit award.
According to the vesting terms, one quarter of the restricted stock units will vest on March 13, 2027, with the remaining three quarters vesting in equal annual installments on each one-year anniversary thereafter, subject to his continued service. For the stock option, one quarter of the shares will vest on March 13, 2027, and the remaining shares will vest in equal monthly installments (1/48th each month) thereafter, also contingent on continued service to the company.
Kyverna Therapeutics’ Chief Executive Officer Biddle Warner Weston received new equity awards as part of his compensation. He was granted stock options for 350,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. One quarter of these options vest on March 13, 2027, with the remaining shares vesting in equal monthly installments of 1/48 each month thereafter, contingent on his continuous service.
He also received a restricted stock unit award covering 58,000 shares of common stock. One quarter of this RSU grant vests on March 13, 2027, and an additional one quarter vests on each one-year anniversary after that date, also subject to continued service. Following these awards, his reported holdings include 58,000 shares of common stock and 350,000 options, reflecting compensation-related acquisitions rather than open-market purchases.
Kyverna Therapeutics, Inc. reported that officer Naji Gehchan received new equity awards as part of compensation. He was granted stock options for 105,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. These options vest over time, with one-fourth vesting on March 13, 2027 and the remaining shares vesting in equal monthly installments thereafter, subject to continued service. He also received a restricted stock unit award covering 18,000 shares of common stock, with one-fourth vesting on March 13, 2027 and the rest vesting in equal annual installments, also subject to continued service.
Kyverna Therapeutics, Inc. filed an initial Form 3 for director Andrew Craig Miller. This filing identifies him as a board member of Kyverna Therapeutics (ticker KYTX) and establishes his status as an insider subject to ongoing ownership reporting requirements.